Étude de phase I-II d'une radiothérapie stéréotaxique hypofractionnée par le cyberknife® pour le traitement de récidive biochimique de cancer de la prostate après un traitement de radiothérapie.
Cyberknife® prostate
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Prostate |
Dr Jean-Paul Bahary
Diane Trudel
514-890-8000 poste 11181
|
La valeur prédictive de la coexistence de la fusion de gène TMPRSS2-ERG et de la suppression de PTEN chez les patients atteints de cancer de la prostate avec récidive biochimique suite à de la radiothérapie de rattrapage ou radicale
PCS VIII
NCT02573636
Actif en recrutement
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
Prostate |
Dr Levon Igidbashian
Solange Tremblay
450-668-1010 poste 23603
|
(EN) Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
PCS-XI
NCT05820633
Actif en recrutement
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
Prostate |
Dr Danny Duplan
Imane Benmouhoub
450-668-1010 poste 23671
|
(EN) A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
MK-5684-003
NCT06136624
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Prostate |
Dre Catherine Sperlich
Marie-Ève Yelle
450-466-5000 poste 3281
|
(EN) A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
EvoPAR-Prostate01
NCT06120491
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Prostate |
Dre Catherine Sperlich
Valérie Painchaud-Lachapelle
450-466-5000 poste 2278
|
(EN) A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
EvoPAR-Prostate01
NCT06120491
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Prostate |
Dr Jean-Benoit Paradis
Sabrina Côté
418-541-1000 poste 3065
|
(EN) Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
PCS-XI
NCT05820633
Actif en recrutement
|
CISSS DE L'OUTAOUAIS
HOPITAL DE GATINEAU
|
Prostate |
Dr Pierre-Yves McLaughlin
Céline Roy
819-966-6100 poste 3669
|
(EN) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
ARASTEP
NCT05794906
Actif en recrutement
|
CISSS DE L'OUTAOUAIS
HOPITAL DE GATINEAU
|
Prostate |
Dr Steven Tisseverasinghe
Céline Roy
819-966-6100 poste 3669
|
(EN) [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer
ACCEL
NCT06229366
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Prostate |
Dr Vincent Castonguay
Carole Plante
418-525-4444 poste 15050
|
(EN) An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer
ASCERTAIN
NCT05938270
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Prostate |
Dr Louis Lacombe
Marilyn Savard
418-525-4444 poste 67703
|